<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351308</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-sarcoma 09</org_study_id>
    <nct_id>NCT04351308</nct_id>
  </id_info>
  <brief_title>Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma</brief_title>
  <acronym>MAPAC</acronym>
  <official_title>A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Sarcoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection
      result in 3-year event-free survival of 60-70%. The most common factors predicting survival
      are presence of metastases, histological response to preoperative chemotherapy and complete
      surgical resection. Four of the active drugs in osteosarcoma include cisplatin, doxorubicin,
      high-dose methotrexate and ifosfamide and this combination (MAPI), given preoperatively and
      postoperatively, is widely used for the treatment of osteosarcoma in China. Apatinib also has
      activity in advanced setting and when incorporated into the treatment of patients with
      metastatic disease seemed to improve progression-free survival. Combination of apatinib and
      camrelizumab resulted in durable therapuetic effect in selected cases. Though EURAMOUS-1
      suggested that changing chemotherapy postoperatively on the basis of histological response
      did not improve outcomes. The exploratory study with radomised design to compare combination
      of chemotherapy with target drug or combination of chemotherapy with anti-PD-1 antibody
      versus standard chemotherapy has not been tried yet. Thus we aim to investigate the efficacy
      and toxicity of these combiantions versus standard chemotherapy in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>from initial treatment after definitive surgery to progression/death/ last follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>from initial treatment after definitive surgery to death/ last follow up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteosarcoma</condition>
  <condition>Survival</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Toxicity, Drug</condition>
  <arm_group>
    <arm_group_label>API+apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)
+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);
I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);
apatinib = 500 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAPI+camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);
camralizumab = 200mg ivgtt. Q2W;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAPI chemotherapy</intervention_name>
    <description>AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²)</description>
    <arm_group_label>API+apatinib</arm_group_label>
    <arm_group_label>MAPI</arm_group_label>
    <arm_group_label>MAPI+camrelizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily</description>
    <arm_group_label>API+apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>anti-PD-1 antibody 200mg ivgtt. Q2W</description>
    <arm_group_label>MAPI+camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high-grade osteosarcoma, including second malignancies

          -  Tumor (primary, metastatic, or both) resectable OR is expected to become resectable
             after neoadjuvant induction chemotherapy

          -  Suitable for neoadjuvant chemotherapy and adjuvant chemotherapy

          -  Performance status - Lansky 50-100% (for patients under 16 years of age); Performance
             status - WHO or ECOG 0-2 with a life expectancy &gt;3 months

          -  normal cardiac function (shortening fraction &gt;28%), normal hearing, normal bone marrow
             as shown by an absolute neutrophil count of at least 1·5 × 10⁹ cells per L (or a white
             blood cell count of at least 3 × 10⁹ cells per L if neutrophil count is not
             available), and a platelet count of at least 100 000 platelets per μL

          -  Patients were also required to have a serum bilirubin concentration of at most less
             than 1·5 times the upper limit of normal and a normal creatinine concentration for
             their age as per protocol

          -  Women of child-bearing potential had to take adequate contraceptive measures and have
             a negative pregnancy test within 7 days of study entry.

        Exclusion Criteria:

          -  patients who have recieved anti-angiogenic TKIs or anti-PD-1/PD-L1 antibodies

          -  allergy to chemotherapy or apatinib or camrelizumab

          -  other severe illness (eg, psychosis or previous history of cardiovascular disease)

          -  symptomatic or known CNS metastases

          -  previous or concurrent second primary malignant tumours

          -  had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine
             protein ≥ ++, and so on

          -  had other infections or wounds

          -  pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Musculoskeletal Tumor Center of Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Xie, M.D.</last_name>
    <phone>+8613401044719</phone>
    <email>xie.lu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Sun, M.D.</last_name>
    <phone>+8613810548607</phone>
    <email>xinsun1981@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Xie, M.D.</last_name>
      <phone>+8613401044719</phone>
      <email>xie.lu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Sun, M.D.</last_name>
      <phone>+8613810548607</phone>
      <email>xinsun1981@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Guo, M.D. and Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>doxirubicin</keyword>
  <keyword>cisplatin</keyword>
  <keyword>methotrexate</keyword>
  <keyword>ifosfamide</keyword>
  <keyword>apatinib</keyword>
  <keyword>camrelizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

